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As cord blood (CB) enables rapid access and tolerance to HLA mismatches, a number 
of unrelated CB transplants have reached 30,000. Such transplant activity has been 
the result of international accreditation programs maintaining highly qualified cord blood 
units (CBUs) reaching more than 600,000 CBUs stored worldwide. Efforts to increase 
stem cell content or engraftment rate of the graft by ex vivo expansion, modulation 
by molecules such as fucose, prostaglandin E2 derivative, complement CD26 inhib-
itors, or CXCR4/CXCL12 axis have been able to accelerate engraftment speed and 
rate. Furthermore, introduction of reduced intensity conditioning protocols, better HLA 
matching, and recognition of the importance of HLA-C have improved CB transplants 
success by decreasing transplant-related mortality. CB progenitor/stem cell content has 
been compared with adult stem cells revealing higher long-term repopulating capacity 
compared to bone marrow–mesenchymal stromal cells and lesser oncogenic potential 
than progenitor-induced stem cells. This chapter summarizes the advantages and dis-
advantages of CB compared to adult stem cells within the context of stem cell biology 
and transplantation.
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Among many sources of hematopoietic stem cell sources, cord blood (CB) is the one that belongs 
to the earliest stages of life. Thus, CB has many features resembling fetal or even embryonic stem 
cells. This review will focus on biological features of CB and comparison of transplants with CB vs. 
adult stem cells.
CORD BLOOD STORAGe wORLDwiDe
More than three million units of CB are currently stored worldwide for autologous or altruistic pur-
poses. Most recent bone marrow donors worldwide (BMDW) website shows that there are 676,446 
unrelated CB units (CBUs) stored in 43 registries. This number is continuously increasing. Although 
CBUs belong to 2.5% of the stem cell pool, thanks to introduction of dCB transplants (dCBT) that 
contribute to approximately 20% of the unrelated stem cell transplants (1, 2). The usual odds ratio is 1 
out of 100 CBUs that meet donor–recipient eligibility/match criteria and are transplanted. For a long 
time, low stem cell content was the major limiting factor against more frequent usage. The previous 
experience among pediatric patients have now expanded to adults, and the number of CB transplants 
has reached 30,000. Allogeneic unrelated CB transplants dominate the annual CBT statistics.
Cord blood units, unlike adult donor stem cell collection/harvests, are readily available on 
demand. Confirmatory HLA Typing and organization of transportation are the few barriers prior 
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to CBT. Hence, CB offers an advantage for patients in need of 
urgent transplantation. As CBTs can be performed with a 4–6/6 
match, this presents a chance of transplantation for patients who 
possess rare HLA types, i.e., who belong to ethnical groups not 
well-represented in registries or who belong to different race 
admixture families.
The HLA data of CBUs in the registries have improved in 
accordance with the required level and extend of typing as for 
the unrelated adult donors. CB banks are encouraged to perform 
collection, transportation, processing, and storage according to 
the standards published and audited by international authorities 
(FACT/NETCORD or AABB). The main purpose is to maintain 
high quality of stem cell products. Post-thaw stem cell counts are 
now being considered as the most important determinant of a 
successful engraftment (3). Purtill et al. have recently shown that 
CBUs from accredited banks engraft better.
AMenDMenT OF MATCHinG CRiTeRiA 
FOR CORD BLOOD
The matching criteria for unrelated CBUs, until very recently, were 
based on low/intermediate HLA-A,-B, and high-resolution HLA-
DRB1 with a minimum match level of ≥4/6. In 2011, the EBMT 
and CIBMTR have published the importance of HLA-C typing. 
Compared to 8/8 matches, those mismatched at HLA-C had a 
higher transplant-related mortality (TRM) (HR: 3.97, p = 0.018). 
A 5/6 mismatch plus a HLA-C mismatch also increased the TRM 
(HR: 1.7, p = 0.029) (4).
Until recently, with the exception of high-resolution HLA-
DRB1 typing, CBUs were typed at low-resolution level for HLA-A 
and -B loci. Recently, Oran et al. (5) have shown better high-reso-
lution HLA-A-, HLA-B-, HLA-C-, and -DRB1-matched cords to 
determine the dominating CBU following double CB transplants. 
Additionally, they did not observe any 2-year transplant-related 
mortality among 7–8/8-matched patients. With increasing num-
ber of mismatches, TRM increased as well. Hence, better match-
ing at a four digit level and four loci increases the success rate.
Although it may seem controversial, the Minnesota group 
recently published allele level mismatching based on the pre-
dominant unit to be only important for prevention of relapse 
(HR: 3.4, p = 0.01) (6). Otherwise, allele level mismatching was 
not associated with any significant detrimental effect on TRM, 
engraftment, or GVHD. In this study, there were only 32 out of 
342 patients who were 9–10/10 allele matched. Although there 
was a reduction in TRM, it was not significant. One additional 
explanation for the difference between these two analyses could 
be due to comparison being performed at five or four loci. The 
Minnesota group proposes to aim for higher cell content units 
to overcome the potential problems that will arise from HLA 
mismatches. They argue a more selective approach trying to 
match CBUs at allelic level will decrease the number of CBTs. 
However, the New York Group has shown that by using a model 
in which both a higher eight-allele HLA match and a cell dose 
≥2.0 × 107/kg/unit were required, graft selection changed in 33% 
of transplants with minimal effect on cell dose (8.3% reduction). 
They conclude that while units chosen based on HLA-A, -B 
antigen, and -DRB1 allele match have substantial mismatch at 
higher resolution, and CB selection based on high-resolution 
HLA match is possible in a significant proportion of patients 
without compromising cell dose (7, 8).
The acceptability of HLA mismatches within the CBT setting 
can also be explained by matching for non-inherited parental 
HLA alleles (9). During pregnancy, fetal lymphocytes may be 
exposed to maternal antigens (NIMA) and gain tolerance. The 
maternal haplotype, which is not inherited can only be recog-
nized by maternal HLA typing. NIMA matching has been shown 
to decrease graft-vs.-host disease (GVHD). CB Registries have 
now initiated the inclusion of maternal HLA types. In the case 
of a NIMA match, the 4/6 match can increase to a virtual 5/6 
match grade. As a result, Europdonor and National Cord Blood 
program have shown that the elucidation of donors’ maternal 
HLA phenotypes can provide significant numbers of 6/6 and 
5/6 virtually matched CBUs to patients and is potentially cost-
effective (10).
In conclusion, recent data favor HLA-C, NIMA, and high-
resolution typing to influence outcome and thus are recom-
mended to be introduced into donor selection criteria. Although 
the role of HLA-C has been ascertained extensively, the impact 
of high-resolution typing and of which locus/loci remains to be 
investigated (6).
The number of HSCs transplanted in a CBT protocol is at 
least one log less than a PBSCT or BMT. On the other hand, 
these cells are cryopreserved and post-thaw viability may range 
between 75 and 99%. The outcome of CBT is affected negatively 
if recipient has developed anti-erythrocyte antibodies or allo-
immunization prior to transplantation. In such situations, to 
avoid engraftment failure, the best HLA match and highest 
CD34 dose are required. However, the New York Group has 
published data negating the effects of allo-immunization (7, 8). 
Although an insignificant delay in median number of days for 
neutrophil engraftment (23 vs. 31 days) was observed, they have 
hypothesized that using an immunosupressive conditioning, 
lack of ATG and double unit grafts abrogates the deleterious 
effects of anti-HLA antibodies.
MODiFiCATiOn OF DOUBLe CORD 
BLOOD TRAnSPLAnT PROTOCOLS
To increase immunosupression as a tool to overcome HLA 
mismatch effects, either fludarabine or ATG has been added to 
the conventional myeloablative conditioning (MAC) regimens. 
As summarized by Ruggeri et al. in the Eurocord/EBMT study, 
two MAC regimens were equally effective (11). The Fludara, 
Busulphan, and Thiotepa regimen (single CBT) or Fludara, 
Cyclophosphamide, and TBI regimens (dCBT) were the MAC 
protocols available widely. The Minnesota Group was the first 
to introduce non-myeloablative approach in CBT (12). The New 
York Group modified this regimen using cyclophosphamide 
(50 mg/kg), fludarabine (150 mg/m2), thiotepa (10 mg/kg), and 
400 cGy total body irradiation with cyclosporine-A/mycopheno-
late mofetil immunosuppression without ATG. As a result they 
were able to achieve engraftment at a median of 26 days among 
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97% (13). Platelets recovered among 93% by day 180. Grades II–IV 
acute GVHD incidence was 67% at day 180, and chronic GVHD 
was 10% at 1 year. TRM was 20% at day 180, and relapse was 11% 
at 2 years. Overall, 2-year disease-free survival (DFS) was 60% at 
2 years. Likewise, Kai et al. have reported results with a myeloa-
blative regimen of CyTBI or CyTBI plus high-dose of cytosine 
arabinoside (14). This study once again proved the importance 
of HLA matching on engraftment. Furthermore, standard risk 
patients obtained a plateau of 67% event-free survival at 3 years 
compared to 29% among advanced disease patients (p = 0.023). 
In conclusion, introduction of NMA or RIC regimens have 
improved engraftment and EFS (40 vs. 60%) (6, 13).
CORD BLOOD AS A SOURCe OF STeM 
CeLLS
Umblical arterial CB vessels transport blood from the fetal 
hepatic circulation to the placental feto-maternal interface to be 
replaced with clean fresh blood devoid of metabolites. Umblical 
venous blood contains fetal cells, which have been in contact 
with placental intervillous syncytothrophoblasts. Oxygen and 
nutrient transport is maintained at this anatomical border 
throughout pregnancy. Placenta is an organ where cells of the 
fetus come into very close proximity but do not meet directly 
with maternal cells. The structure of placenta allows contact of 
fetal syncytothrophoblasts with maternal blood cells or decidua 
cells called interstitial trophoblasts. Successful pregnancy is 
maintained with suppression of immune reactivity either by lack 
of surface HLA expression, secretion of IGF-1/2, LIF, or TGF. 
This highly immunosuppressive environment contributes to the 
metabolomic profile of CB.
For many years, CB has been used for hematopoietic stem cell 
transplantation only. Recently, CB mesenchymal stromal cells 
(MSCs) have become clinically available. There is an estimated 
frequency of 1,000–5,000 MSCs in a typical UCB unit of approxi-
mately 100 mL (15). The main advantage of using CB-MSC is to 
enhance engraftment and to prevent or to treat GVHD. MSCs can 
be obtained from multiple sources, i.e., bone marrow, adipose or 
dental tissues, CB or Wharton’s jelly and even menstrual blood.
COMPARiSOn OF MSC FROM DiFFeRenT 
SOURCeS
Comparison of MSCs obtained from different sources has been 
a topic of interest for many years. The decline in MSC number 
and differentiation potential with increasing age is a disadvantage 
against adult tissues, such as BM or adipose tissues. A comparison 
by Kern et al. was able to find no significant differences concern-
ing the morphology and immune phenotype of the MSCs derived 
from different sources. However, differences could be observed 
concerning the success rate of isolating MSCs, which was 100% 
for BM and AT, but only 63% for UCB. The colony frequency was 
lowest in UCB, whereas it was highest in AT. However, UCB–MSCs 
possessed the longest culture period and showed the highest 
proliferation capacity, BM-MSCs possessed the shortest culture 
period and the lowest proliferation capacity. In a more recent 
study by Trivanović et al., in addition to immuno-phenotyping, 
proliferation and differentiation gene expression assays were also 
performed. Peripheral blood MSCs (PB-MSCs) and UC-MSCs 
showed the highest, while periodontal ligament MSCs (PDL-
MSCs) and adipose tissue MSCs (AT-MSCs) the lowest values 
of both the replication potential and Relative Telomere Length. 
Although MSCs from exfoliated deciduous teeth (SHEDs), 
PDL-MSCs, and AT-MSCs showed higher mRNA expression of 
pluripotency markers, all MSCs expressed pluripotency marker 
proteins (16).
These two studies have shown that UC-MSCs have the highest 
proliferation rate and transplantation capacity than other MSCs 
(16, 17). If the origin is Wharton Jelly, MSCs are cultured effi-
ciently because these cells are maintained in an early embryologic 
phase and therefore have retained some of the primitive stemness 
property resulting with a high proliferative capacity (18).
COMPARiSOn OF CB vS. iPS
One argument against storage of CB has arisen following success-
ful generation of induced progenitor cells (IPSC). As these IPSCs 
have features similar to embryonic stem cells and can be obtained 
from adult tissues, they can be used in the same individual in 
need and from whom they were obtained. Currently, there are 
major obstacles against their routine use in clinical transplanta-
tion: their safety has not yet been proven and the production is 
very expensive and limited to advanced sites only.
Recently, a study comparing the MSC from CB vs. IPSC has 
shown that the CB MSC’s expression level of pluripotent genes 
OCT4 and Sox-2, Nanog and lin28 were significantly higher than 
those in IPSCs. In contrast, the expression level of oncogenic 
factors c-Myc and Klf4 were significantly higher in IPSCs than in 
CB-MSC. In conclusion, the authors suggested that CB-MSC is 
may be less oncogenic than IPSC. (19)
BeneFiCiAL iMMUnOLOGiCAL 
FeATUReS OF CORD BLOOD
The typical feature of CB lymphocytes is as follows: the majority 
consists of antigen-inexperienced naïve lymphocytes, which are 
less responsive to allo-stimulation with a low effector cytokine 
production capacity. Furthermore, regulatory T cells (T regs) are 
seen more frequently. UCB dendritic cells have a lower antigen 
presenting activity. All these features are protective against 
GVHD but may predispose to graft failure or delay in immune 
reconstitution (20, 21).
On the other hand, UCB is rich in primitive CD16−CD56++ 
NK cells, which possess impressive proliferative and cytotoxic 
capacities and can be induced to expand using IL-12 or IL-15, 
so as to mount a substantial graft-vs.-leukemia (GvL) effect. The 
composition of CB mononuclear cells by Tregs and primitive NK 
cells is an ideal combination serving the purpose of GVL in the 
setting of allogeneic stem cell transplantation. This topic has been 
extensively addressed in a chapter in this issue of the journal.
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EX VIVO eXPAnSiOn AnD 
enGRAFTMenT enHAnCeRS
Unlike all the factors addressed above, methods of CB expansion 
and engraftment include the most innovative approaches in the 
field of CBT and CB banking. They are described in detail in the 
current issue and elsewhere (22, 23, Beksac and Yurdakul, under 
review for publication in the same Research Topic).
In conclusion, this ready to use stem cell product has many 
clinically proven indications and protocols. More recent proto-
cols for matching and transplantation have proven to improve 
transplant success. Furthermore methods under pre- and clinical 
investigations are very promising toward even better outcomes. 
As one of the pioneers in CBT has said this is a great time for those 
involved in CB biology and transplantation.
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